VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab ...

Patients who received Vyvgart Hytrulo experienced a longer time to clinical deterioration compared with those who received placebo. The Food and Drug Administration (FDA) has approved Vyvgart ® ...

(RTTNews) - argenx SE (ARGX) said that the U.S. Food and Drug Administration has accepted for priority review a supplemental Biologics License Application or sBLA for VYVGART Hytrulo (efgartigimod ...

The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo ...

The U.S. FDA has approved a label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, letting a broader section of adults suffering from the autoimmune disease receive the therapy, its ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2.2 billion in sales last year, argenx has scored FDA approval for a new ...

Efgartigimod alfa, hyaluronidase-qvfc; 1000mg/10000Units (per prefilled syringe), 1008mg/11200Units (per vial); soln for SC inj; preservative-free. Store prefilled syringes or vials refrigerated at ...

The US Food and Drug Administration (FDA) has approved argenx’s Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy ...

Shares in Argenx have been taking a bashing this morning after the company announced its new subcutaneous formulation of Vyvgart had missed the mark in another phase 3 trial. The Netherlands-based ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...